IO Biotech (IOBT)
Market Price (4/7/2026): $0.054 | Market Cap: $3.6 MilSector: Health Care | Industry: Biotechnology
IO Biotech (IOBT)
Market Price (4/7/2026): $0.054Market Cap: $3.6 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -375% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Weak multi-year price returns2Y Excs Rtn is -123%, 3Y Excs Rtn is -162% | Penny stockMkt Price is 0.0 Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -92 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2644% High stock price volatilityVol 12M is 235% Key risksIOBT key risks include [1] the pivotal Phase 3 trial failure of its lead candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -375% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -123%, 3Y Excs Rtn is -162% |
| Penny stockMkt Price is 0.0 |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -92 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2644% |
| High stock price volatilityVol 12M is 235% |
| Key risksIOBT key risks include [1] the pivotal Phase 3 trial failure of its lead candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. IO Biotech filed for Chapter 7 bankruptcy and ceased all operations.
On March 31, 2026, IO Biotech announced it ceased operations and filed a voluntary petition for Chapter 7 bankruptcy in Delaware, indicating that it is highly unlikely common shareholders will receive any recovery. This move effectively liquidates the company's assets under the control of a court-appointed trustee.
2. The lead therapeutic cancer vaccine candidate, Cylembio®, narrowly missed statistical significance in its pivotal Phase 3 trial.
In November 2025, IO Biotech reported that its Phase 3 IOB-013 trial for Cylembio® in combination with pembrolizumab in advanced melanoma showed a clinically relevant improvement in progression-free survival (PFS) of 19.4 months versus 11.0 months for pembrolizumab alone. However, the trial narrowly missed its prespecified statistical significance threshold (p=0.056 compared to a threshold of p≤0.045). This outcome led the FDA to recommend against a Biologics License Application (BLA) based on the data, necessitating a new registrational study and contributing to a 50% workforce reduction in Q3 2025.
Show more
Stock Movement Drivers
Fundamental Drivers
The -92.1% change in IOBT stock from 12/31/2025 to 4/6/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 12312025 | 4062026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.61 | 0.05 | -92.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 67 | 67 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
12/31/2025 to 4/6/2026| Return | Correlation | |
|---|---|---|
| IOBT | -92.1% | |
| Market (SPY) | -5.4% | 1.6% |
| Sector (XLV) | -5.5% | -17.5% |
Fundamental Drivers
The -86.8% change in IOBT stock from 9/30/2025 to 4/6/2026 was primarily driven by a -1.6% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 9302025 | 4062026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.36 | 0.05 | -86.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 66 | 67 | -1.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
9/30/2025 to 4/6/2026| Return | Correlation | |
|---|---|---|
| IOBT | -86.8% | |
| Market (SPY) | -2.9% | 2.1% |
| Sector (XLV) | 5.6% | -10.5% |
Fundamental Drivers
The -95.6% change in IOBT stock from 3/31/2025 to 4/6/2026 was primarily driven by a -1.6% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 3312025 | 4062026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.09 | 0.05 | -95.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 66 | 67 | -1.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2025 to 4/6/2026| Return | Correlation | |
|---|---|---|
| IOBT | -95.6% | |
| Market (SPY) | 16.3% | 3.5% |
| Sector (XLV) | 1.6% | -0.5% |
Fundamental Drivers
The -97.4% change in IOBT stock from 3/31/2023 to 4/6/2026 was primarily driven by a -57.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 3312023 | 4062026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.88 | 0.05 | -97.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 29 | 67 | -57.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2023 to 4/6/2026| Return | Correlation | |
|---|---|---|
| IOBT | -97.4% | |
| Market (SPY) | 63.3% | 7.6% |
| Sector (XLV) | 18.3% | 3.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| IOBT Return | -59% | -64% | -18% | -51% | -34% | -95% | -100% |
| Peers Return | 16% | -36% | 3% | -34% | -19% | 13% | -54% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -4% | 75% |
Monthly Win Rates [3] | |||||||
| IOBT Win Rate | 0% | 25% | 42% | 42% | 42% | 25% | |
| Peers Win Rate | 52% | 37% | 45% | 42% | 47% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| IOBT Max Drawdown | -59% | -65% | -63% | -64% | -61% | -95% | |
| Peers Max Drawdown | -27% | -56% | -38% | -40% | -54% | -15% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MRNA, IOVA, AGEN, NEO, REGN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/6/2026 (YTD)
How Low Can It Go
| Event | IOBT | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -94.6% | -25.4% |
| % Gain to Breakeven | 1752.1% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to MRNA, IOVA, AGEN, NEO, REGN
In The Past
IO Biotech's stock fell -94.6% during the 2022 Inflation Shock from a high on 11/5/2021. A -94.6% loss requires a 1752.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About IO Biotech (IOBT)
AI Analysis | Feedback
An early-stage Merck or Bristol Myers Squibb focused on next-generation cancer immunotherapies.
Like Moderna or BioNTech, but developing platform-based cancer immunotherapies instead of vaccines.
A pioneering clinical-stage biotech, much like Genentech was, but specializing in therapies that awaken the immune system to fight cancer.
AI Analysis | Feedback
- IO102-IO103: A lead product candidate designed to target immunosuppressive proteins like IDO and PD-L1 for the treatment of various cancers, currently in Phase 1 and Phase 2 clinical trials.
- IO112: A product candidate containing an Arginase 1-derived peptide designed to target T cells that recognize Arginase 1 epitopes for the treatment of cancers.
AI Analysis | Feedback
IO Biotech (IOBT) is a clinical-stage biopharmaceutical company. As described in the background, its product candidates, such as IO102-IO103 and IO112, are currently in various phases of clinical trials (Phase 1 and Phase 2). Companies at this stage are primarily focused on research, development, and clinical testing, and do not yet have commercialized products available for sale.Therefore, IO Biotech does not currently have major customers, either individuals or other companies, as its products are still under development and have not yet received regulatory approval for commercial sale.
AI Analysis | Feedback
```html null ```AI Analysis | Feedback
Mai-Britt Zocca, Ph.D. Founder, President & CEO Dr. Zocca has served as the founder and Chief Executive Officer of IO Biotech since January 2015. She also founded and served as CEO of OncoNOx ApS from July 2011 until May 2019. Prior to founding IO Biotech, she was the CEO at LevOss ApS from January 2012 to January 2017 and led DanDrit Biotech A/S as CEO from July 2007 to December 2010. Amy Sullivan, M.B.A. Chief Financial Officer Ms. Sullivan joined IO Biotech as Chief Financial Officer in October 2022. She brings over 25 years of life sciences experience, specializing in capital raising and corporate brand management. Before joining IO Biotech, she was CFO of TABA, BV. She also served as Chief Strategy Officer for Euronext-listed Kiadis Pharma, where she was instrumental in fundraising, repositioning the company after a clinical failure, and played a critical role in its sale to Sanofi. Additionally, Ms. Sullivan was Senior Vice President of Corporate Affairs at Keryx Biopharmaceuticals during a period of significant growth, the commercialization of its first FDA-approved medicine, and a merger. Qasim Ahmad, M.D. Chief Medical Officer Dr. Ahmad is a trained internist and clinical oncologist with over two decades of experience in strategic clinical development, medical affairs, and marketing authorization expertise. He joined IO Biotech from Novartis, where he most recently served as Senior Vice President, US Head of Clinical Development & Medical Affairs for the Novartis Oncology business unit. Faiçal Miyara, Ph.D. Chief Business Officer Dr. Miyara is an executive with nearly two decades of experience in the pharmaceutical and biotechnology industry, with a track record of successful deals and partnerships. He previously served as Vice President, Head of Business Development Oncology, and then Head of External Innovation Oncology, Lead on Venture Capital Activities at Ipsen Biosciences. Before Ipsen, he was Senior Vice President, Head of Business Development and External Research at Kadmon Corporation. Marjan Shamsaei, PharmD Senior Vice President Commercial and Portfolio Lead Dr. Shamsaei is an accomplished executive with over 25 years of experience in the pharmaceutical and biotechnology industry, focusing on developing commercial and portfolio strategies across multiple therapeutic areas. She most recently served as Vice President, Head of Commercial at Allogene Therapeutics. Her previous leadership roles include positions at Five Prime Therapeutics (acquired by Amgen), Genentech, Jazz Pharmaceuticals, and SUGEN/Pharmacia (acquired by Pfizer).AI Analysis | Feedback
Key Risks to IO Biotech (IOBT)
- Clinical Trial and Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, IO Biotech's success is heavily dependent on the successful outcome of its ongoing clinical trials for product candidates like IO102-IO103 (in Phase 2) and IO112, and subsequent regulatory approvals. There is a significant risk that these candidates may fail to demonstrate efficacy or safety in later-stage trials, or may not receive approval from regulatory bodies, which would severely impact the company's viability.
- Commercialization and Market Adoption Risk: Even if IO Biotech's product candidates receive regulatory approval, there is a substantial risk associated with their successful commercialization and market adoption. The company would need to effectively manufacture, market, and distribute its products, establish pricing, and gain acceptance from healthcare providers and patients in a competitive market, which requires significant resources and expertise that a clinical-stage company may not fully possess.
- Competition Risk: The field of immune-modulating cancer therapies is highly competitive, with numerous pharmaceutical and biotechnology companies developing and commercializing similar or alternative treatments. IO Biotech's product candidates, if approved, will face intense competition from existing therapies and new treatments entering the market, which could limit their market share, pricing power, and overall commercial success.
AI Analysis | Feedback
```html null ```AI Analysis | Feedback
Here are the addressable market sizes for IO Biotech's main products:IO Biotech's lead product candidate, IO102-IO103, targets melanoma, lung, head and neck, and bladder cancers. The company also develops IO112 for the treatment of cancers. The addressable markets for these indications are as follows:
- Melanoma: The global melanoma therapeutics market was estimated at USD 9.16 billion in 2024 and is projected to reach USD 21.79 billion by 2033. Another source estimated the global melanoma therapeutics market size at USD 5.83 billion in 2024, projected to reach USD 10.26 billion by 2030. North America holds a significant share of this market, with the U.S. having the largest patient pool and market for treatment. The U.S. melanoma market has been revolutionized by advancements in immunotherapy and targeted therapy.
- Lung Cancer: The global lung cancer therapeutics market was valued at USD 33.19 billion in 2024 and is expected to reach USD 73.29 billion by 2032. Another estimate places the global market at USD 35.1 billion in 2024, projected to grow to USD 95.1 billion in 2034. The U.S. lung cancer therapeutics market was valued at USD 15.4 billion in 2024. North America is a dominant region in the lung cancer therapeutics market.
- Head and Neck Cancer: The global head and neck cancer therapeutics market size was estimated at USD 2.53 billion in 2025 and is projected to reach USD 6.25 billion by 2033. Another report estimates the global market at USD 2.54 billion in 2026, growing to USD 4.46 billion by 2031. North America held the largest share of the global market, at 44.63% in 2025.
- Bladder Cancer: The global bladder cancer therapeutics diagnostics market size was approximately USD 5.36 billion in 2024 and is projected to reach USD 9.53 billion by 2034. Another source indicates the global bladder cancer market size reached USD 3.9 billion in 2023 and is expected to reach USD 5.4 billion by 2034. For the U.S. specifically, the non-muscle invasive bladder cancer treatment market size was estimated at approximately USD 1.45 billion in 2023, while the U.S. bladder cancer therapeutics diagnostics market was USD 1.58 billion in 2024, projected to reach USD 2.86 billion by 2034. North America, particularly the U.S., represents a significant market for bladder cancer treatment.
AI Analysis | Feedback
IO Biotech (IOBT) is a clinical-stage biopharmaceutical company focused on developing immune-modulating cancer therapies based on its proprietary T-win technology platform. Over the next 2-3 years, the company's future revenue growth is expected to be driven by several key factors:
-
Potential Commercialization of Cylembio (IO102-IO103) for Advanced Melanoma
The primary driver of future revenue growth for IO Biotech hinges on the successful regulatory approval and commercial launch of its lead product candidate, Cylembio (IO102-IO103), for the treatment of advanced melanoma. While topline data from a Phase 3 clinical trial in advanced melanoma (IOB-013) presented in the third quarter of 2025 narrowly missed statistical significance on the primary progression-free survival (PFS) endpoint, the results supported the mechanism of action of their therapeutic cancer vaccines. IO Biotech is scheduled to meet with the FDA in December 2025 to discuss the design of a potential new Phase 3 registrational trial. Despite a revised regulatory pathway and a lowered probability of success for 1L melanoma to 30% from 50% by some analysts, the company still anticipates filing a Biologics License Application (BLA) with the FDA by year-end 2025. Analysts project increasing royalty revenues from partnerships, estimated to rise significantly from $6.1 million in fiscal year 2027 to $88.3 million by fiscal year 2032, contingent upon successful product launches. IO Biotech retains global commercial rights to IO102-IO103.
-
Expansion of Cylembio (IO102-IO103) into Additional Oncology Indications
Beyond advanced melanoma, IO Biotech is actively investigating Cylembio (IO102-IO103) for other challenging cancer types, which could serve as significant revenue growth drivers. The company reported positive results from a Phase 2 trial of IO102-IO103 in the first-line treatment of advanced squamous cell carcinoma of the head and neck (SCCHN) in September 2024, meeting the primary endpoint of overall response rate. Additionally, IO102-IO103 is undergoing a Phase 2 basket trial (IOB-022/KN-D38) in combination with pembrolizumab for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) and recurrent/metastatic SCCHN. Enrollment for a Phase 2 basket trial evaluating Cylembio as a neoadjuvant/adjuvant treatment for resectable melanoma or head and neck cancer was completed ahead of schedule, with initial data expected in the second half of 2025. The company is also studying IO102/IO103 in metastatic urothelial cancer. Successful progression and potential approval in these additional indications would significantly expand the addressable market for IO Biotech's lead candidate.
-
Advancement of IO112 into Clinical Development
The progression of IO Biotech's second therapeutic cancer vaccine candidate, IO112, represents another important future revenue driver. IO112 targets Arginase 1, an immunosuppressive protein overexpressed in several cancers. Pre-clinical data has shown IO112's anti-tumor activity and its ability to induce dynamic changes in the tumor microenvironment. The company anticipates filing an Investigational New Drug (IND) Application for IO112 in 2026, which would enable its entry into further clinical trials. Successful advancement through clinical development for IO112 would add another potential product to IO Biotech's pipeline, contributing to revenue growth beyond the immediate 2-3 year horizon.
AI Analysis | Feedback
Share Issuance
- In August 2023, IO Biotech completed a private placement, generating approximately $75 million in gross proceeds through the issuance of 37,065,647 shares of common stock and accompanying warrants.
- Between July and September 2025, the company received net proceeds of $6.6 million from an at-the-market program.
Inbound Investments
- In August 2023, IO Biotech secured approximately $75 million in gross proceeds through a private placement from new and existing healthcare-dedicated investors.
- IO Biotech entered into a loan facility with the European Investment Bank (EIB), drawing Tranche A of €10.0 million in May 2025 and Tranche B of €12.5 million in July 2025, totaling €22.5 million (approximately $24.4 million) in loan proceeds.
Trade Ideas
Select ideas related to IOBT.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 5.89 |
| Mkt Cap | 1.2 |
| Rev LTM | 495 |
| Op Inc LTM | -90 |
| FCF LTM | -79 |
| FCF 3Y Avg | -117 |
| CFO LTM | -79 |
| CFO 3Y Avg | -115 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.1% |
| Rev Chg 3Y Avg | 8.8% |
| Rev Chg Q | 10.6% |
| QoQ Delta Rev Chg LTM | 2.6% |
| Op Mgn LTM | -18.0% |
| Op Mgn 3Y Avg | -80.2% |
| QoQ Delta Op Mgn LTM | 0.9% |
| CFO/Rev LTM | -67.6% |
| CFO/Rev 3Y Avg | -79.2% |
| FCF/Rev LTM | -67.6% |
| FCF/Rev 3Y Avg | -97.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.2 |
| P/S | 5.1 |
| P/EBIT | -1.7 |
| P/E | -1.7 |
| P/CFO | -0.9 |
| Total Yield | -12.6% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -19.7% |
| D/E | 0.2 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -8.8% |
| 3M Rtn | 8.6% |
| 6M Rtn | 10.7% |
| 12M Rtn | 21.9% |
| 3Y Rtn | -57.7% |
| 1M Excs Rtn | -7.6% |
| 3M Excs Rtn | 11.2% |
| 6M Excs Rtn | 13.1% |
| 12M Excs Rtn | -8.7% |
| 3Y Excs Rtn | -125.0% |
Price Behavior
| Market Price | $0.05 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 11/05/2021 | |
| Distance from 52W High | -98.0% | |
| 50 Days | 200 Days | |
| DMA Price | $0.27 | $0.95 |
| DMA Trend | down | down |
| Distance from DMA | -82.2% | -94.9% |
| 3M | 1YR | |
| Volatility | 362.5% | 236.6% |
| Downside Capture | 5.42 | 1.37 |
| Upside Capture | -321.86 | -156.48 |
| Correlation (SPY) | 0.5% | 2.8% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.09 | 0.50 | 0.12 | 0.40 | 0.41 | 0.74 |
| Up Beta | 7.10 | 4.73 | -2.90 | -1.37 | 0.55 | 0.52 |
| Down Beta | -1.70 | -3.00 | -3.44 | 0.20 | 0.75 | 1.03 |
| Up Capture | -134% | 60% | -226% | -62% | -49% | -0% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 6 | 13 | 23 | 52 | 101 | 318 |
| Down Capture | 370% | 241% | 259% | 70% | 38% | 100% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 16 | 28 | 39 | 72 | 136 | 395 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IOBT | |
|---|---|---|---|---|
| IOBT | -95.4% | 235.9% | -0.03 | - |
| Sector ETF (XLV) | 2.8% | 17.6% | 0.00 | -1.1% |
| Equity (SPY) | 15.3% | 19.0% | 0.64 | 3.4% |
| Gold (GLD) | 49.6% | 28.0% | 1.44 | -1.3% |
| Commodities (DBC) | 15.5% | 17.7% | 0.74 | -3.2% |
| Real Estate (VNQ) | 3.1% | 16.5% | 0.01 | 0.0% |
| Bitcoin (BTCUSD) | -19.0% | 44.0% | -0.35 | -2.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IOBT | |
|---|---|---|---|---|
| IOBT | -68.3% | 138.6% | -0.24 | - |
| Sector ETF (XLV) | 6.1% | 14.5% | 0.24 | 5.8% |
| Equity (SPY) | 11.7% | 17.0% | 0.53 | 11.6% |
| Gold (GLD) | 21.8% | 17.8% | 1.01 | 0.6% |
| Commodities (DBC) | 11.6% | 18.8% | 0.50 | 0.2% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.09 | 7.0% |
| Bitcoin (BTCUSD) | 3.0% | 56.5% | 0.27 | 4.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IOBT | |
|---|---|---|---|---|
| IOBT | -43.7% | 138.6% | -0.24 | - |
| Sector ETF (XLV) | 9.9% | 16.5% | 0.49 | 5.8% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 11.6% |
| Gold (GLD) | 14.0% | 15.9% | 0.73 | 0.6% |
| Commodities (DBC) | 8.4% | 17.6% | 0.39 | 0.2% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.21 | 7.0% |
| Bitcoin (BTCUSD) | 65.9% | 66.9% | 1.05 | 4.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/14/2025 | 1.7% | -9.2% | -15.2% |
| 8/11/2025 | -42.0% | 19.3% | -0.6% |
| 5/14/2025 | -2.0% | 3.0% | 50.0% |
| 3/4/2025 | -1.6% | -3.5% | 17.0% |
| 11/12/2024 | -11.7% | -16.7% | -19.6% |
| 8/13/2024 | 17.7% | 12.3% | -37.3% |
| 5/14/2024 | 2.1% | -2.1% | -9.2% |
| 3/5/2024 | 2.5% | 6.8% | 1.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 8 | 6 |
| # Negative | 4 | 7 | 9 |
| Median Positive | 2.1% | 9.7% | 22.0% |
| Median Negative | -6.8% | -9.2% | -19.6% |
| Max Positive | 17.7% | 55.3% | 50.0% |
| Max Negative | -42.0% | -20.7% | -37.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/05/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/14/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/16/2022 | 10-Q |
| 12/31/2021 | 03/31/2022 | 10-K |
Recent Forward Guidance [BETA]
Latest: Q3 2025 Earnings Reported 11/14/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Cash Runway | |||||||
Prior: Q2 2025 Earnings Reported 8/14/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Cash Runway | |||||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hunter, Heidi | Direct | Buy | 6022025 | 1.39 | 15,000 | 20,884 | 20,884 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.